In Hep C, Will Achillion Succeed Where Gilead, Merck Did Not?
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Phase II trial pairing NS5A inhibitor ACH-3102 with Gilead’s Sovaldi produces 100% cure rate with six weeks of therapy, leading multiple analysts to call Achillion candidate best-in-class.